Alaunos Therapeutics (TCRT) Invested Capital (2021 - 2023)

Alaunos Therapeutics (TCRT) has 3 years of Invested Capital data on file, last reported at $11.0 million in Q1 2023.

• Quarterly Invested Capital fell 54.81% year-over-year to $11.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $11.0 million (down 87.55% YoY) and the FY2022 annual result came in at $16.8 million, down 30.49% from the prior year.
• Invested Capital slipped to $11.0 million in Q1 2023, from $16.8 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $24.5 million in Q2 2022 to a low of $11.0 million in Q1 2023.
• A 3-year average of $21.1 million and a median of $24.1 million in 2021 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital dropped 6.37% — and 2023, when it tumbled 54.81%.
• Tracing TCRT's Invested Capital over 3 years: stood at $24.1 million in 2021, then slumped by 30.49% to $16.8 million in 2022, then plunged by 34.46% to $11.0 million in 2023.
• The last three Invested Capital figures came in at $11.0 million (Q1 2023), $16.8 million (Q4 2022), and $22.7 million (Q3 2022), per Business Quant data.